Keyphrases
Non-muscle Invasive Bladder Cancer (NMIBC)
100%
Bladder Recurrence
100%
Chemotherapy
50%
Urological Symptoms
50%
General Well-being
50%
Adverse Events
50%
Prospective Randomized Trial
50%
Recurrence Rate
50%
Bladder Cancer
50%
Anticancer Activity
50%
Tumor Recurrence
50%
Metastatic Disease
50%
Clinical Efficacy
50%
Pain Frequency
50%
Urination
50%
Oncological Treatment
50%
Cancer 2
50%
Nocturia
50%
Bladder Cancer Cells
50%
Intravesical Treatment
50%
Oncology Care
50%
Medicine and Dentistry
Bladder Cancer
100%
Cancer Recurrence
100%
Oncology
66%
Non Muscle Invasive Bladder Cancer
66%
Recurrent Disease
33%
Cancer Cell
33%
Adverse Event
33%
Weakness
33%
Metastatic Carcinoma
33%
Recurrence Risk
33%
Wellbeing
33%
Tumor Recurrence
33%
Micturition
33%
Antineoplastic Activity
33%
Mycobacterium Bovis BCG
33%
Nocturia
33%
Pain (Symptom)
33%
Intravesical Drug Administration
33%
Pharmacology, Toxicology and Pharmaceutical Science
Bladder Cancer
100%
Cancer Recurrence
100%
Non Muscle Invasive Bladder Cancer
66%
Malignant Neoplasm
33%
Symptom
33%
Chemotherapy
33%
Recurrent Disease
33%
Weakness
33%
Adverse Event
33%
Metastasis
33%
Recurrence Risk
33%
Tumor Recurrence
33%
Mycobacterium Bovis BCG
33%
Nocturia
33%